Literature DB >> 24911575

Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.

Hidenobu Suzuki1, Keishi Gen, Masahiro Otomo, Yuichi Inoue, Hiroyuki Hibino, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikami.   

Abstract

OBJECTIVE: We investigated the relationship between the plasma concentration of paliperidone (PAL) and clinical and drug-induced extrapyramidal symptoms (EPS) in elderly patients with schizophrenia.
METHODS: In this study, 15 patients with schizophrenia receiving risperidone were switched to PAL and treated for 12 weeks. Their clinical symptoms were assessed using the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity of Illness Scale. Their EPS were assessed using the Drug-induced EPS Scale, Abnormal Involuntary Movement Scale, and Barnes Akathisia Scale at baseline and 12 weeks. Plasma concentrations were measured by the liquid chromatography-mass spectrometry/mass spectrometry method.
RESULTS: The results revealed that there were significant correlations between the plasma concentration of PAL and improved Positive and Negative Syndrome Scale total, negative, and general psychopathology scores (p<0.05). However, the efficacy did not improve linearly with plasma level. No significant correlations were found between the PAL plasma concentration and the mean change from baseline in the Drug-induced EPS Scale total score, Barnes Akathisia Scale, or Abnormal Involuntary Movement Scale.
CONCLUSIONS: The results of this research suggested that, in elderly patients, although none of an increased plasma concentration of PAL, a worsening of EPS, or an increase in prolactin level occurs, linear clinical efficacy may not be obtained.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  efficacy; elderly schizophrenia; paliperidone; plasma concentration; safety

Mesh:

Substances:

Year:  2014        PMID: 24911575     DOI: 10.1002/hup.2393

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  2 in total

1.  Serum Concentration of Paliperidone Palmitate Administered Every 3 Weeks.

Authors:  Johan Y Cohen; Ariane Dumoulin-Charette; Nafaa Meraabi; Raphaël Poirier
Journal:  Psychopharmacol Bull       Date:  2019-06-20

2.  Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation.

Authors:  Arne Helland; Olav Spigset
Journal:  Ther Drug Monit       Date:  2017-12       Impact factor: 3.681

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.